Mirum Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for MIRM, updated each market day.
MIRM AI Sentiment
AI sees no strong directional signal for Mirum Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Sector
Exchange
Market Cap
$6,792,698,875
Cap Tier
Employees
372
Headquarters
FOSTER CITY, CA
Listed Since
July 18, 2019
Website
MIRM Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MIRM Volatility
Mirum Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
